Subscribe: MedWorm: Chemotherapy
http://www.medworm.com/rss/medicalfeeds/therapies/Chemotherapy.xml
Added By: Feedage Forager Feedage Grade B rated
Language: English
Tags:
breast cancer  cancer  chemotherapy  health  lung cancer  lung  medical  new  news  patients  source eurekalert  source 
Rate this Feed
Rate this feedRate this feedRate this feedRate this feedRate this feed
Rate this feed 1 starRate this feed 2 starRate this feed 3 starRate this feed 4 starRate this feed 5 star

Comments (0)

Feed Details and Statistics Feed Statistics
Preview: MedWorm: Chemotherapy

MedWorm: Chemotherapy News



MedWorm.com provides a medical RSS filtering service. Thousands of medical RSS feeds are combined and output via different filters. This feed contains the latest news in Chemotherapy



Last Build Date: Wed, 25 Apr 2018 10:33:42 +0100

 



Circulating Tumor Cell Count Predicts Early Breast Cancer Outcomes Circulating Tumor Cell Count Predicts Early Breast Cancer Outcomes

Tue, 24 Apr 2018 22:58:19 +0100

Circulating tumor cell (CTC) count independently predicts outcomes in women with early breast cancer treated with neoadjuvant chemotherapy, according to a meta-analysis.Reuters Health Information (Source: Medscape Pathology Headlines)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.




Removing the enablers: Reducing number of tumor-supporting cells to fight neuroblastoma

Mon, 23 Apr 2018 04:00:00 +0100

(Children's Hospital Los Angeles) Investigators at the Children's Center for Cancer and Blood Diseases at Children's Hospital Los Angeles provide preclinical evidence that the presence of tumor-associated macrophages -- a type of immune cell -- can negatively affect the response to chemotherapy against neuroblastoma. Their findings suggest that combination therapy might be effective in patients with high-risk disease, even those who have limited anti-tumor T cell responses. (Source: EurekAlert! - Cancer)



Chemotherapy Induced Oral Mucositis: Prevention Is Possible Chemotherapy Induced Oral Mucositis: Prevention Is Possible

Fri, 20 Apr 2018 04:14:53 +0100

Does a mouthwash containing soluble prednisolone, nystatin, and salt reduce the rate of oral mucositis associated with chemotherapy?Chinese Clinical Oncology (Source: Medscape Today Headlines)



NHS WILL fund breast cancer tests that could spare women the stress of chemotherapy

Fri, 20 Apr 2018 03:07:08 +0100

Almost 10,000 women a year are to benefit from NHS breast cancer tests that could spare them the stress of chemotherapy after a U-turn by Nice. (Source: the Mail online | Health)



FDA Approves Intravenous Formulation of Akynzeo (fosnetupitant/palonosetron) for Chemotherapy-Induced Nausea and Vomiting

Fri, 20 Apr 2018 03:04:20 +0100

Lugano, Switzerland April 20, 2018 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, today announces that the U.S. Food and Drug Administration (FDA) has approved the intravenous formulation of Akynzeo... (Source: Drugs.com - New Drug Approvals)



Mayo Clinic Q and A: Curious about acupuncture?

Fri, 20 Apr 2018 00:00:00 +0100

DEAR MAYO CLINIC: I started chemotherapy last month, and my health care provider suggested I try acupuncture for nausea. How does acupuncture work? Is there any risk to trying it? ANSWER: Traditional Chinese medicine, including acupuncture, dates back more than 2,500 years. Acupuncture involves inserting thin, single-use, sterile needles through the skin to identify and [...] (Source: News from Mayo Clinic)

MedWorm Message: If you are looking to buy something in the January Sales please visit TheJanuarySales.com for a directory of all the best sales in the UK. Any income gained via affiliate links keeps MedWorm running.




Venetoclax/Rituximab Found Superior to Chemotherapy in CLL

Thu, 19 Apr 2018 21:07:47 +0100

The combination of rituximab and the BCL2 inhibitor venetoclax significantly lengthened PFS among CLL patients in the phase III MURANO trial. (Source: CancerNetwork)



Medical News Today: Added to chemotherapy, this drug doubles lung cancer survival

Thu, 19 Apr 2018 14:00:00 +0100

Adding immunotherapy to chemotherapy doubled survival in a trial of metastatic nonsquamous non-small cell lung cancer lacking EGFR and ALK mutations. (Source: Health News from Medical News Today)



Lung Cancer Treatment, Immunotherapy and Chemotherapy

Thu, 19 Apr 2018 09:44:08 +0100

A recent study showed dramatic results in treating lung cancer with an immunotherapy drug in tandem with chemotherapy. ... The combo achieved a large survival rate. ... Two other studies similarly ... (Source: AARP.org News)



Elderly less likely to benefit from simultaneous radio- & chemotherapy for lung cancer

Thu, 19 Apr 2018 04:00:00 +0100

(European Society for Radiotherapy and Oncology (ESTRO)) An analysis of elderly patients treated in a phase II trial of radiotherapy combined with chemotherapy in non-small cell lung cancer has shown that they were less likely to benefit than younger patients if the two treatments were given at the same time. The study is presented at ESTRO37 -- Europe's largest radiation oncology conference. (Source: EurekAlert! - Cancer)



BIDMC-lead team develops new approach to study long non-coding RNAs

Thu, 19 Apr 2018 04:00:00 +0100

(Beth Israel Deaconess Medical Center) In a groundbreaking paper, investigators at the Cancer Research Institute Beth Israel Deaconess Medical Center developed a novel approach to identify and determine the functional role of lncRNAs relevant to chemotherapy resistance in Acute Myeloid Leukemia (AML). The new technique integrates information from publicly-available pharmacological data bases with leading-edge CRISPR technologies to screen for both coding and non-coding genes that influence response to treatment. (Source: EurekAlert! - Cancer)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.




Study may explain why some triple-negative breast cancers are resistant to chemotherapy

Thu, 19 Apr 2018 04:00:00 +0100

(University of Texas M. D. Anderson Cancer Center) Triple-negative breast cancer (TNBC) is an aggressive form of the disease accounting for 12 to 18 percent of breast cancers. It is a scary diagnosis, and even though chemotherapy can be effective as standard-of-care, many patients become resistant to treatment. A team at The University of Texas MD Anderson led a study which may explain how resistance evolves over time, and potentially which patients could benefit from chemotherapy. (Source: EurekAlert! - Cancer)



Behind enemy lines

Wed, 18 Apr 2018 19:08:20 +0100

Chemotherapy is modern medicine ’s first line of defense against cancer: chemotherapy drugs kill dividing cells by damaging DNA, preventing tumor cells from multiplying and tumors themselves from growing. To pick which chemotherapy regimens to use, oncologists rely on broad guidelines, based on the average success rates of chemo therapies. But these guidelines don’t take into account the genetic diversity of tumors, which can make some tumors drug resistant. (Source: UCSF School of Pharmacy News)



OncoMasTR Assay May Help Some Breast Cancer Patients Avoid Chemo

Wed, 18 Apr 2018 17:37:46 +0100

In this video, Dr. Arman Rahman explains how the OncoMasTR protein assay may help women with breast cancer avoid unnecessary chemotherapy. (Source: CancerNetwork)



Gene mapping can help doctors pick most appropriate chemotherapy

Wed, 18 Apr 2018 15:27:25 +0100

Researchers have devised a new gene mapping technique that allows medical providers to determine the chemotherapy with the fewest side effects and best success. (Source: Health News - UPI.com)



How chemotherapy induces infertility

Wed, 18 Apr 2018 12:00:00 +0100

Researchers have described the mechanism that explains infertility in women who undergo chemotherapy, a study inNature Structural& Molecular Biology suggests.Science Daily (Source: Society for Endocrinology)

MedWorm Message: If you are looking to buy something in the January Sales please visit TheJanuarySales.com for a directory of all the best sales in the UK. Any income gained via affiliate links keeps MedWorm running.




Detailed images of tumor vasculature

Wed, 18 Apr 2018 04:00:00 +0100

(Ruhr-University Bochum) Thanks to a new method of analyzing ultrasound images, conventional scanners can be used for generating high-res images of blood vessels in tumors. This approach makes it easier to distinguish between different types of tumors, and it facilitates the tracking of the progress and success of chemotherapy. (Source: EurekAlert! - Medicine and Health)



Study: Drug, chemo combo double survival in metastatic lung cancer

Tue, 17 Apr 2018 13:54:48 +0100

Combining the immunotherapy drug pembrolizumab with chemotherapy doubles survival in patients with some forms of lung cancer compared with chemo alone. (Source: Health News - UPI.com)



Immunotherapy study yields "dramatic results" against lung cancer

Tue, 17 Apr 2018 13:13:45 +0100

In a major advance in the treatment of lung cancer, researchers found that adding immunotherapy, drugs designed to trigger a patient's immune system, to standard chemotherapy cuts a patient's risk of dying or having the cancer worsen within one year in half. Dr. David Agus joins "CBS This Morning" from Los Angeles to discuss the "groundbreaking" study and what the development means for treating other cancers. (Source: Health News: CBSNews.com)



Latest Mesothelioma Immunotherapy Combination Looks Promising

Tue, 17 Apr 2018 13:05:59 +0100

Scientists at the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital have uncovered a novel, two-agent immunotherapy combination that worked surprisingly well in animal models with malignant mesothelioma. The discovery has sparked new optimism for immunotherapy, which has struggled to provide consistently positive results with aggressive cancers such as mesothelioma. “This is the beginning of a new story of hope, a new combination of immunotherapy,” Dr. Mark Poznansky, director of the VIC and associate professor at Harvard Medical School, told Asbestos.com. “It worked quite well in aggressive mouse models. It looks promising for humans.” The combination involves AMD3100 (plerixafor) — an immune modulator that already has approval from the U.S. Food and Drug ...



Novocure touts top-line data from Ph2 mesothelioma trial

Tue, 17 Apr 2018 13:04:53 +0100

Novocure (NSDQ:NVCR) today touted positive top-line data from its Phase II pilot mesothelioma trial and revealed that it plans to submit a humanitarian device exemption application to the FDA for approval. The St. Helier, N.J.-based company reported that patients who received treatment with its “Tumor Treating Fields” system plus chemotherapy experienced clinically meaningful improvements in overall survival and progression-free survival compared to historical control data. Get the full story at our sister site, Drug Delivery Business News. The post Novocure touts top-line data from Ph2 mesothelioma trial appeared first on MassDevice. (Source: Mass Device)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.




TMB as New Biomarker in NSCLC -- Ready for Clinic? TMB as New Biomarker in NSCLC -- Ready for Clinic?

Tue, 17 Apr 2018 12:12:53 +0100

A new biomarker -- high tumor mutational burden (TMB) -- identifies lung cancer patients who do better on immunotherapy than on chemotherapy.Medscape Medical News (Source: Medscape Medical News Headlines)



Pembro Plus Chemo: Practice-Changing for mNSCLC Pembro Plus Chemo: Practice-Changing for mNSCLC

Tue, 17 Apr 2018 12:03:01 +0100

Adding pembrolizumab to chemotherapy provided significant improvement in both overall and progression-free survival; the results have been hailed as practice-changing.Medscape Medical News (Source: Medscape Pathology Headlines)



Pembro Plus Chemo: Practice-Changing for Nonsquamous mNSCLC Pembro Plus Chemo: Practice-Changing for Nonsquamous mNSCLC

Tue, 17 Apr 2018 12:03:01 +0100

Adding pembrolizumab to chemotherapy provided significant improvement in both overall and progression-free survival; the results have been hailed as practice-changing.Medscape Medical News (Source: Medscape Medical News Headlines)



Immune therapy doubles lung cancer survival rate

Tue, 17 Apr 2018 11:24:56 +0100

New drugs that trigger a patient ’s immune system to kill malignant cells can greatly improve the survival rate of people with the most common type of lung cancer, a new study found. The study, published in the New England Journal of Medicine, found that patients treated with the checkpoint inhibitor pembrolizumab, or Keytruda, made by Merck, along with chemotherapy  were 51 percent less likely to die compared with patients that only received chemotherapy, The Washington Post reports. The study… (Source: bizjournals.com Health Care:Physician Practices headlines)



Management of Chemo-Induced Alopecia With Scalp Cooling Management of Chemo-Induced Alopecia With Scalp Cooling

Tue, 17 Apr 2018 04:15:32 +0100

Is scalp-cooling technology more effective for decreasing alopecia from taxane-based or anthracycline-based chemotherapy regimens?Journal of Oncology Practice (Source: Medscape Today Headlines)

MedWorm Message: If you are looking to buy something in the January Sales please visit TheJanuarySales.com for a directory of all the best sales in the UK. Any income gained via affiliate links keeps MedWorm running.




Gene mapping lays groundwork for precision chemotherapy

Tue, 17 Apr 2018 04:00:00 +0100

(University of California - San Francisco) Despite the great successes of targeted cancer drugs and the promise of novel immunotherapies, the vast majority of people diagnosed with cancer are still first treated with chemotherapy. Now a new study by UCSF researchers using techniques drawn from computational biology could make it much easier for physicians to use the genetic profile of a patient's tumor to pick the chemotherapy treatment with the fewest side effects and best chance of success. (Source: EurekAlert! - Medicine and Health)



Preserving fertility during chemotherapy

Tue, 17 Apr 2018 04:00:00 +0100

(Goethe University Frankfurt) One of the most significant impairments of the quality of life after a chemotherapy is infertility. Researchers of the Goethe University and the University Tor Vergata in Rome have now identified the mechanism of chemotherapy-induced infertility in females. (Source: EurekAlert! - Social and Behavioral Science)



Diagnosing, treating neuropathy symptoms in cancer patients not exact science

Tue, 17 Apr 2018 04:00:00 +0100

(University of Michigan) Most of the roughly 15.5 million cancer survivors in the US receive chemotherapy, and roughly 65 percent develop some degree of the chemotherapy-induced nerve damage known as peripheral neuropathy. (Source: EurekAlert! - Medicine and Health)



In Nonsquamous Lung Cancer, a New Standard of Care (CME/CE)

Tue, 17 Apr 2018 02:35:03 +0100

(MedPage Today) -- NSCLC patients see big survival boost with pembrolizumab plus chemotherapy (Source: MedPage Today Hematology/Oncology)



Immunotherapy drug DOUBLES survival in lung cancer patients

Mon, 16 Apr 2018 22:12:40 +0100

Merck's Keytruda, given with standard chemotherapy, cut in half the risk of dying or having the cancer worsen, compared to chemo alone after nearly one year. (Source: the Mail online | Health)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.




These are the top priorities for the nation ’s top cancer doctor

Mon, 16 Apr 2018 20:00:33 +0100

Norman “Ned” Sharpless still remembers one of his favorite patients — a 40-ish woman with breast cancer whose chemotherapy treatment stopped working. During one visit, she told him she knew she wouldn’t be cured but hoped to live just six more years, long enough to see her 11-year-old daughter graduate from high school. “It did […]Related:For advanced lung cancer, immune therapy plus chemo prolongs survivalThis 3-year-old has ‘a sparkle’ in her heart: The world’s smallest mechanical heart valveFDA restricts sale of Essure contraceptive device, requires that women be informed of risks (Source: Washington Post: To Your Health)



These are the top priorities for the nation ’ s top cancer doctor

Mon, 16 Apr 2018 20:00:33 +0100

Norman “Ned”’ Sharpless still remembers one of his favorite patients — a 40-ish woman with breast cancer whose chemotherapy treatment stopped working. During one visit, she told him she knew she wouldn't be cured but hoped to live just six more years, long enough to see her 11-year-old daughter graduate from high school. “It did […]Related:For advanced lung cancer, immune therapy plus chemo prolongs survivalThis 3-year-old has ‘a sparkle’ in her heart: The world’s smallest mechanical heart valveFDA restricts sale of Essure contraceptive device, requires that women be informed of risks (Source: Washington Post: To Your Health)



Adjuvant Pembrolizumab Beneficial in Metastatic NSCLC

Mon, 16 Apr 2018 19:00:33 +0100

MONDAY, April 16, 2018 -- For metastatic non-small-cell lung cancer (NSCLC), the addition of pembrolizumab to standard chemotherapy is beneficial; and nivolumab plus ipilimumab is associated with better survival than chemotherapy for NSCLC with high... (Source: Drugs.com - Pharma News)



Survival data boosts Merck's Keytruda lead in lung cancer

Mon, 16 Apr 2018 15:35:50 +0100

(Reuters) - Merck& Co's immunotherapy Keytruda plus chemotherapy significantly improved overall survival in newly-diagnosed patients with advanced non-small cell lung cancer in a closely-watched study, cementing its lead position over Bristol-Myers Squibb Co and others in the most lucrative oncology market. (Source: Reuters: Health)



Lung Cancer Patients Live Longer With Immune Therapy

Mon, 16 Apr 2018 13:49:05 +0100

Adding immunotherapy to standard chemo treatments can halve the risk of death for people with the most common type of lung cancer, a new study shows. (Source: NYT Health)

MedWorm Message: If you are looking to buy something in the January Sales please visit TheJanuarySales.com for a directory of all the best sales in the UK. Any income gained via affiliate links keeps MedWorm running.




Merck, Bristol-Myers immunotherapies impress in key lung cancer trials

Mon, 16 Apr 2018 13:48:03 +0100

(Reuters) - Merck& Co's immunotherapy Keytruda plus chemotherapy significantly improved overall survival versus chemotherapy alone in newly-diagnosed patients with advanced non-small cell lung cancer in a highly-anticipated study that appears to cement the company's lead in the most lucrative oncology market. (Source: Reuters: Health)



Treatment combo nearly doubles lung cancer survival time

Mon, 16 Apr 2018 13:35:20 +0100

Combining an immunotherapy drug with chemotherapy nearly doubled the survival time of some lung cancer patients compared to patients treated with chemotherapy alone, new research published Monday in the New England Journal of Medicine showed. (Source: CNN.com - Health)



Treatment combo nearly doubles survival time in lung cancer patients, study finds

Mon, 16 Apr 2018 13:35:20 +0100

Combining an immunotherapy drug with chemotherapy nearly doubled the survival time of some lung cancer patients compared to patients treated with chemotherapy alone, new research published Monday in the New England Journal of Medicine showed. (Source: CNN.com - Health)



New Studies Show Immune Treatments Could Be Key in the Fight Against Lung Cancer

Mon, 16 Apr 2018 13:30:40 +0100

Researchers report some of the most encouraging results yet for treating lung cancer with the latest immune-based treatments, most of which have been approved to treat other types of tumors. In three papers presented at the American Association for Cancer Research annual meeting, and published simultaneously in the New England Journal of Medicine, lung cancer experts found innovative ways to weaken lung tumors to improve people’s chances of surviving the disease. “There is definitely a high unmet need,” says Patrick Forde, assistant professor of oncology and associate member of the Bloomberg-Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, of the lack of effective treatments for lung cancer. Currently more than half of people who are treated even at early stage...



For advanced lung cancer, immune therapy plus chemo prolongs survival

Mon, 16 Apr 2018 13:30:00 +0100

Patients with newly diagnosed advanced lung cancer who received an immunotherapy drug plus standard chemotherapy lived significantly longer than those who got chemo alone, according to a new study that is expected to change the way such patients are treated. The report was one of several highly anticipated studies on immunotherapy and lung cancer presented Monday […]Related:This 3-year-old has ‘a sparkle’ in her heart: The world’s smallest mechanical heart valveFDA restricts sale of Essure contraceptive device, requires that women be informed of risksWith $2 million, Kaiser Permanente wants to help revive underfunded gun-violence research (Source: Washington Post: To Your Health)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.




Pleurectomy and Decortication the ‘ Way to Go ’ for Mesothelioma

Mon, 16 Apr 2018 13:04:22 +0100

Dr. Pietro Bertoglio and his colleagues at the University Hospital of Pisa stopped performing the aggressive extrapleural pneumonectomy (EPP) surgery for mesothelioma more than a decade ago. They believe it’s long overdue for everyone else to do the same and instead use the less-debilitating pleurectomy/decortication (P/D) procedure. The Journal of Thoracic and Cardiovascular Surgery recently published the University Hospital of Pisa’s 10-year experience using P/D and hyperthermic intrathoracic chemotherapy (HITHOC). Two editorial commentaries from thoracic surgeons in the U.S. accompanied the study from Italy, supporting it to varying degrees. “I’m sure this [P/D surgery] is the way to go now with mesothelioma,” Bertoglio told Asbestos.com. “It just gives the patient the bette...



Man-made antibodies show promise in attacking cancer cells in animal models

Mon, 16 Apr 2018 04:00:00 +0100

(Duke University Medical Center) Using chemotherapy along with aptamers -- lab-made molecules that function like antibodies -- Duke Health researchers showed that they can zero in on and kill prostate cancer tumors in mice while leaving healthy tissue unscathed. (Source: EurekAlert! - Cancer)



Combination therapy doubles survival in metastatic lung cancer

Mon, 16 Apr 2018 04:00:00 +0100

(NYU Langone Health / NYU School of Medicine) The immunotherapy drug pembrolizumab, combined with chemotherapy, doubles survival in patients with non-squamous non-small cell lung cancer (NSNSCLC) lacking genetic changes in the EGFR or ALK genes, when compared to chemotherapy alone, according to an international, Phase III clinical trial. (Source: EurekAlert! - Cancer)



New liquid biopsy-based cancer model reveals data on deadly lung cancer

Sun, 15 Apr 2018 04:00:00 +0100

(University of Texas M. D. Anderson Cancer Center) Small cell lung cancer (SCLC) accounts for 14 percent of all lung cancers and is often rapidly resistant to chemotherapy resulting in poor clinical outcomes. Treatment has changed little for decades, but a study at The University of Texas MD Anderson Cancer Center offers a potential explanation for why the disease becomes chemoresistant, and a possible avenue to explore new diagnostic approaches. (Source: EurekAlert! - Cancer)



A3AR Agonists May Help Prevent Chemotherapy-Induced Neuropathic Pain

Fri, 13 Apr 2018 21:44:59 +0100

A highly selective small molecule A3AR agonist blocked development of oxaliplatin-induced neuropathic pain without interfering with anticancer effects. (Source: CancerNetwork)

MedWorm Message: If you are looking to buy something in the January Sales please visit TheJanuarySales.com for a directory of all the best sales in the UK. Any income gained via affiliate links keeps MedWorm running.




Inhibiting metabolism found to be effective in treating aggressive form of lung cancer

Fri, 13 Apr 2018 04:18:43 +0100

FINDINGSResearchers from UCLA and Long Beach Memorial Medical Center have found that two targeted therapies could be more effective if used in combination to treat squamous cell carcinomas of the lung. The two drugs, MLN128 and CB-839, individually target the metabolism of key nutrients glucose and glutamine, respectively, prohibiting the cancer from switching metabolic gears between glucose (a simple sugar) and glutamine (an amino acid) to tap vital sources of energy. This switch enables the cancer cells to adapt their metabolism and evade treatments.BACKGROUNDNon-small cell lung cancer makes up about 85 percent of all lung cancers, and within this population about 20 percent of patients get squamous cell carcinomas. These carcinomas are aggressive and highly resistant to most current the...



Chemotherapy-Associated Neuropathy in Early Breast Cancer Chemotherapy-Associated Neuropathy in Early Breast Cancer

Fri, 13 Apr 2018 04:14:54 +0100

Neuropathic symptoms may persist in over 80% of patients receiving adjuvant chemotherapy for early breast cancer.Journal of the National Cancer Institute (Source: Medscape Today Headlines)



Is IO Monotherapy the New Standard of Care in Advanced NSCLC? Is IO Monotherapy the New Standard of Care in Advanced NSCLC?

Wed, 11 Apr 2018 14:55:44 +0100

Merck has released provocative but limited findings from the KEYNOTE-042 trial that indicate better outcomes for first-line pembrolizumab vs standard chemotherapy in advanced non-small cell lung cancer (NSCLC).Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)



Simultaneous chemo and immunotherapy may be better for some with metastatic bladder cancer

Wed, 11 Apr 2018 04:00:00 +0100

(The Mount Sinai Hospital / Mount Sinai School of Medicine) Researchers from Mount Sinai and Sema4, a health information company and Mount Sinai venture, have discovered that giving metastatic bladder cancer patients simultaneous chemotherapy and immunotherapy is safe and that patients whose tumors have certain genetic mutations may respond particularly well to this combination approach, according to the results of a clinical trial published in European Urology. (Source: EurekAlert! - Cancer)



Brentuximab Vedotin Approved for Classical HL

Tue, 10 Apr 2018 21:57:29 +0100

The FDA has approved brentuximab vedotin (Adcetris) to treat adults with previously untreated stage III or IV cHL, in combination with chemotherapy. (Source: CancerNetwork)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.




Early 'chemobrain' intervention needed for breast cancer patients undergoing chemotherapy

Tue, 10 Apr 2018 04:00:00 +0100

(National University of Singapore) More support is needed to help breast cancer patients and survivors manage 'chemobrain' symptoms, such as memory loss, short attention span and mental confusion, according to a study led by researchers from the National University of Singapore.   (Source: EurekAlert! - Cancer)



New drug combo improves survival of women with rare uterine cancer

Tue, 10 Apr 2018 04:00:00 +0100

(Johns Hopkins Medicine) Adding the monoclonal antibody drug trastuzumab -- already used to treat certain breast cancers -- to the chemotherapy regimen of women with a rare form of uterine cancer lengthens the amount of time their tumors are kept from growing, according to Johns Hopkins Medicine researchers conducting a small phase II trial of the regimen, testing its safety and value (Source: EurekAlert! - Cancer)



Pembrolizumab Offers Better QOL vs Chemo in Advanced Urothelial Cancer

Mon, 09 Apr 2018 19:23:31 +0100

Pembrolizumab offered stable or improved measures of global health status and quality of life compared with chemotherapy in patients with previously treated advanced urothelial cancer. (Source: CancerNetwork)



5 Key Takeaways from Mesothelioma Expert Teleconference

Mon, 09 Apr 2018 18:26:05 +0100

If you have been diagnosed with mesothelioma, you’re likely seeking information and resources to learn more about the disease. A free one-hour mesothelioma teleconference is a great place to start. CancerCare recently hosted the “Advancements in the Treatment of Mesothelioma” workshop. The session featured five mesothelioma experts, including Dr. Hedy Kindler, director of the mesothelioma program at the University of Chicago Comprehensive Cancer Center. The Mesothelioma Applied Research Foundation co-sponsored the teleconference, which is available online for free. All mesothelioma patients can benefit from the topics covered, including an overview of the disease, treatment options, importance of clinical trials, how to communicate with your health care team and other important issu...



Activity of Ceragenin CSA-131 against Candida Auris

Mon, 09 Apr 2018 12:56:40 +0100

Published Research Shows Ceragenin CSA-131 ’s Potent Efficacy against Candidaauris, a New Serious Global Health ThreatDUBLIN, OHIO – April 5, 2018 – N8 Medical, LLC today announced a peer-reviewed publication in The Journal ofAntimicrobial Chemotherapy with U.S. Centers for Disease Control and Prevention (CDC) co-authors of promisingefficacy data regarding the activity of ceragenin CSA-131 against 100 strains of Candida auris (C. auris) collected fromaround the world. (Source: The Aspergillus Website - updates)

MedWorm Message: If you are looking to buy something in the January Sales please visit TheJanuarySales.com for a directory of all the best sales in the UK. Any income gained via affiliate links keeps MedWorm running.




How tumors caused by STD quickly regress in dogs

Mon, 09 Apr 2018 04:00:00 +0100

(Cell Press) The canine transmissible venereal tumor is a contagious cancer that has spread by mating among dogs worldwide. One unique feature of this cancer is that, for unclear reasons, it regresses spontaneously or a few weeks after a single treatment of radiotherapy or chemotherapy. A study published April 9 in the journal Cancer Cell shines a light on this mystery, revealing a key role for the immune system in triggering fast cancer rejection in chemotherapy-treated dogs. (Source: EurekAlert! - Cancer)



Breast cancer therapy: All clear for the heart

Mon, 09 Apr 2018 04:00:00 +0100

(German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ)) Many breast cancer therapies cause damage to the heart. However, in the largest study of its kind so far, scientists from the German Cancer Research Center (DKFZ) in Heidelberg have now shown that the risk of death from heart disease in breast cancer patients following radiotherapy or chemotherapy is no higher than it is among the average population. Good risk management in the hospitals as well as control screenings at short intervals seem to make up for elevated risks. (Source: EurekAlert! - Medicine and Health)



Biomarker helps identify 'window of opportunity' for cancer chemotherapy timing

Mon, 09 Apr 2018 04:00:00 +0100

(Elsevier) Angiogenesis, the formation of new blood vessels, is essential for tumor growth. A new study reported in The American Journal of Pathology describes a vascular stabilization biomarker that can visualize blood vessel activity, thus optimizing the timing of anticancer therapies including anti-angiogenics. (Source: EurekAlert! - Cancer)



Maharashtra to start free chemotherapy units in 10 district hospitals

Sat, 07 Apr 2018 00:00:00 +0100

The plan will start with hospitals in Nagpur, Gadchiroli, Pune, Amravati, Jalgaon, Nashik, Wardha, Satara, Bhandara and Akola, an official release said. (Source: The Economic Times)



Chemotherapy medication errors

Fri, 06 Apr 2018 12:14:12 +0100

This article summarises available evidence on the extent and nature of medication errors in cancer chemotherapy, and discusses how they can be reduced (incident reporting, proactive risk assessment, administration protocols, guidelines and checklists, education, and IT systems). (Source: Current Awareness Service for Health (CASH))

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.




Leukemia, and Its Treatment, May Pose Neurocognitive Risks

Fri, 06 Apr 2018 12:00:23 +0100

FRIDAY, April 6, 2018 -- Underlying leukemia, even before chemotherapy, may pose a neurocognitive risk to young patients, according to a study published online March 29 in JAMA Oncology. Yin Ting Cheung, Ph.D., from the St. Jude Children's Research... (Source: Drugs.com - Pharma News)



Herbal treatments help balance hormone fluctuations and mood swings in women

Fri, 06 Apr 2018 10:19:41 +0100

(Natural News) Menopause is a natural occurrence wherein menstruation stops in women. It typically occurs between the ages of 45 and 55. However, menopause can also occur before the age of 40. Menopause can be purposefully induced by drugs for medical reasons or prematurely caused by surgery, radiotherapy, chemotherapy and other drugs, or caused by... (Source: NaturalNews.com)



TNT Is Viable for Locally Advanced Rectal Cancer

Fri, 06 Apr 2018 00:19:46 +0100

CR was 36% in the total neoadjuvant therapy cohort vs 21% in the cohort that received chemoradiotherapy with adjuvant chemotherapy. (Source: CancerNetwork)



Doctors shocked when cannabis oil cures woman of terminal cancer

Thu, 05 Apr 2018 11:40:01 +0100

(Natural News) There is no shortage of patients curing their cancer on their own, with a little help from a medicinal plant we call cannabis. Recently, a 52-year-old woman from the United Kingdom revealed that cannabis oil saved her life. After a terminal cancer diagnosis and failed chemotherapy treatments, Joy Smith says that she was willing... (Source: NaturalNews.com)



Mesothelioma Clinical Trial Opens with Optimism in South Florida

Wed, 04 Apr 2018 13:08:42 +0100

Dr. Chukwuemeka Ikpeazu at the Sylvester Comprehensive Cancer Center has brought hope — where once there was none — to patients in South Florida with unresectable pleural mesothelioma. Ikpeazu is the principal investigator in the multicenter phase II clinical trial involving the much-anticipated immunotherapy drug durvalumab. Pharmaceutical giant AstraZeneca manufactures the drug under the brand name Imfinzi. “I am optimistic, very, very optimistic that this drug will be effective for these patients,” Ikpeazu told Asbestos.com. “All the data, all the earlier studies, are encouraging.” He recently enrolled his first mesothelioma patient in the trial and expects others to follow shortly. Durvalumab will be used as a first-line treatment in combination with standard-of-care chemot...

MedWorm Message: If you are looking to buy something in the January Sales please visit TheJanuarySales.com for a directory of all the best sales in the UK. Any income gained via affiliate links keeps MedWorm running.




Updated ASTRO guideline for palliative lung RT recommends concurrent chemo for some stage III pts

Wed, 04 Apr 2018 04:00:00 +0100

(American Society for Radiation Oncology) The American Society for Radiation Oncology (ASTRO) today issued an update to its clinical guideline for the use of palliative-intent radiation therapy for patients with incurable non-small cell lung cancer (NSCLC). Reflecting new evidence from randomized clinical trials, the guideline now recommends the addition of concurrent chemotherapy to radiation therapy for certain patients with incurable stage III NSCLC, including those who are able to tolerate chemotherapy and have a life expectancy longer than three months. (Source: EurekAlert! - Cancer)



'I'm so lucky my cancer was spotted after budget cuts hit screening' says LORD LANSLEY

Tue, 03 Apr 2018 23:01:00 +0100

LAST Monday, I sat in a chair in a medical day unit while chemotherapy medication went into my vein. A drug called oxaliplatin which, with daily tablets of capecitabine to follow, are my ongoing treatment for bowel cancer. (Source: Daily Express - Health)



Smith & Nephew to name ex-Alere chief exec Nawana as CEO

Tue, 03 Apr 2018 21:11:21 +0100

Smith & Nephew (NYSE:SNN) is slated to announce tomorrow that it has tapped former Alere (NYSE:ALR) CEO Namal Nawana as its new chief executive officer, according to a report from Sky News. The company has been searching for a replacement since last October, when current head Olivier Bohoun announced plans to retire from the corner office. Bohoun announced his retirement plans after having been diagnosed with a “highly treatable” type of cancer in February 2016, but said he planned to stay at the reins while undergoing treatment, including chemotherapy. Australian-native Nawana took over as CEO at Alere in 2014 after founder and then-CEO Ron Zwanzinger stepped down. Zwanzinger received criticisms for his leadership after he spiked an initial public offering for its BBI Di...



Total Neoadjuvant Approach Promising in Locally Advanced Rectal Cancer Total Neoadjuvant Approach Promising in Locally Advanced Rectal Cancer

Tue, 03 Apr 2018 20:22:36 +0100

Preoperative chemotherapy in combination with chemoradiation (total neoadjuvant therapy, or TNT) appears to have advantages over traditional approaches to treating locally advanced rectal cancer, according to new research.Reuters Health Information (Source: Medscape General Surgery Headlines)



Independent Review: Offer Scalp Cooling With Breast Cancer Chemo Independent Review: Offer Scalp Cooling With Breast Cancer Chemo

Tue, 03 Apr 2018 17:14:37 +0100

A review of data concludes that scalp cooling is safe and effective for the prevention of chemotherapy-induced alopecia, particularly for breast cancer patients receiving a taxane-based regimen.Medscape Medical News (Source: Medscape Medical News Headlines)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.




Three cancer survivors sue the fertility clinic that lost their frozen eggs  

Tue, 03 Apr 2018 15:29:36 +0100

Three cancer survivors announced yesterday that they will sue University Hospitals in Cleveland, where a cryogenic tank failure destroyed the eggs they had delayed their chemotherapy to freeze. (Source: the Mail online | Health)



Cancer survivors discuss pain of losing eggs to fertility clinic failure

Tue, 03 Apr 2018 12:13:10 +0100

All three women allege they risked their lives by delaying chemotherapy to undergo painful fertility treatments (Source: Health News: CBSNews.com)



Cancer survivors sue Ohio fertility clinic

Tue, 03 Apr 2018 12:04:36 +0100

Three cancer survivors are suing the Cleveland-area fertility clinic that accidentally destroyed more than 4,000 stored embryos and eggs. All three woman allege they risked their lives by delaying chemotherapy to undergo painful fertility treatments. Dr. Tara Narula reports. (Source: Health News: CBSNews.com)



Protein derived from parasite has potential to alleviate debilitating disease

Tue, 03 Apr 2018 04:00:00 +0100

(Children's National Health System) A Children's-led research team has turned the tables on Schistosoma haematobium, a parasitic worm that freeloads in humans, by using a protein derived from the parasite as a therapeutic molecule to reduce bleeding and pain associated with chemotherapy-induced hemorrhagic cystitis. (Source: EurekAlert! - Cancer)



Testicular Cancer May Lead to Heart Trouble Later

Mon, 02 Apr 2018 22:51:38 +0100

In the study, Abu Zaid and his colleagues analyzed 486 testicular cancer survivors who were treated with platinum-based chemotherapy. The investigators found that these patients had higher-than-normal rates of heart disease risk factors. (Source: WebMD Health)

MedWorm Message: If you are looking to buy something in the January Sales please visit TheJanuarySales.com for a directory of all the best sales in the UK. Any income gained via affiliate links keeps MedWorm running.




Two-pronged approach could curb many cases of lung cancer

Mon, 02 Apr 2018 04:00:00 +0100

(Boston Children's Hospital) Lung cancer, a leading killer, has been hard to target with drugs. A team at Boston Children's Hospital took a metabolic approach, looking at what lung tumor cells need to live and grow. When they removed these factors, tumor growth was almost completely suppressed in a mouse model. Their findings suggest that a combination of existing drugs (IGF-1 inhibitors and inhibitors of protein breakdown) could provide an alternative to chemotherapy in curbing this deadly cancer. (Source: EurekAlert! - Cancer)



Woman, 33, who blamed indigestion on stress diagnosed with stage 4 colon cancer

Fri, 30 Mar 2018 22:26:26 +0100

Diana Zepeda, 33, has just finished chemotherapy for stage 4 colon cancer after spending nearly two years thinking her symptoms were just results of her poor diet and stressful life in Washington, DC. (Source: the Mail online | Health)



Excellent IDEA: Shorter Adjuvant Chemo in Colon Cancer Excellent IDEA: Shorter Adjuvant Chemo in Colon Cancer

Fri, 30 Mar 2018 15:13:58 +0100

For some patients with stage III colon cancer, 3 months of adjuvant chemotherapy was just as effective as 6 months, but with less toxicity.Medscape Medical News (Source: Medscape Medical News Headlines)



T2 Biosystems touts results from 4 studies of its T2Dx diagnostics system

Fri, 30 Mar 2018 14:47:22 +0100

T2 Biosystems this week released results from four studies of its T2Dx blood diagnostics system designed to detect pathogens that cause sepsis, touting clinical and performance advantages when compared to traditional blood cultures. The four studies were published in the Journal of Antimicrobial Chemotherapy, the Lexington, Mass.-based company said. A study conducted at Rome’s Gemelli Hospital examined the use of the T2Bacteria panel on the T2Dx, and found that positive results were produced 4.5 times faster at 5.5 hours versus 25 hours with a standard blood culture. Negative results on the T2Bacteria panel were produced 20 times faster at 6.1 hours versus 120 hour for blood cultures. The T2Bacteria panel had a reported 89.5% sensitivity and 98.4% specificity in comparison with clin...



Mesothelioma Clinical Trial Evaluating Selecta ’ s SEL-403 Begins

Thu, 29 Mar 2018 13:46:51 +0100

A clinical trial testing a new therapeutic modality on patients with pleural and peritoneal mesothelioma is officially underway. Selecta Biosciences, a clinical-stage biopharmaceutical company, and the National Cancer Institute (NCI) teamed up for the phase 1 clinical trial under the Cooperative Research and Development Agreement. The trial will evaluate safety and tolerability of SEL-403, Selecta’s investigational new drug combination consisting of a potent anti-tumor agent (LMB-100) and a drug that prevents an immune response (SVP-Rapamycin). LMB-100 and SVP-Rapamycin have been studied separately in clinical trials. Researchers hope combining the two therapies will improve effectiveness and increase the number of treatments patients can receive before there is an antibody response and ...

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.




Three-month chemo as 'effective as six after bowel cancer surgery'

Thu, 29 Mar 2018 06:14:00 +0100

Many patients receiving chemotherapy following surgery for bowel cancer may only need three months treatment rather than the six months currently given, according to researchers. (Source: Nursing Times)



Neurocognitive risk may begin before treatment for young leukemia patients

Thu, 29 Mar 2018 04:00:00 +0100

(St. Jude Children's Research Hospital) Chemotherapy agents have been associated with neurocognitive side effects in young leukemia survivors. Now St. Jude Children's Research Hospital scientists have evidence the disease and genetics might also play a role. (Source: EurekAlert! - Cancer)



Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors

Wed, 28 Mar 2018 16:14:12 +0100

This review concludes that keratinocyte growth factor is beneficial in the prevention of oral mucositis in adults who are receiving radiotherapy to the head and neck with cisplatin or fluorouracil, or chemotherapy alone for mixed solid and haematological cancers. (Source: Current Awareness Service for Health (CASH))



Global cancer trial sets new standard for post-surgery chemotherapy

Wed, 28 Mar 2018 04:00:00 +0100

(SWOG) Some stage III colon cancer patients can cut in half the number of chemotherapy treatments they receive after surgery, significantly reducing the costs, treatment time, and long-term toxic effects of chemotherapy, according to results of a unique global clinical trial collaboration published for the first time in the New England Journal of Medicine. (Source: EurekAlert! - Cancer)



James F. Holland, Trailblazing Cancer Researcher, Dies at 92

Tue, 27 Mar 2018 21:23:31 +0100

Dr. Holland was called a founding father of chemotherapy, collaborating on drug combinations to contain childhood leukemia and other tumors. (Source: NYT Health)

MedWorm Message: If you are looking to buy something in the January Sales please visit TheJanuarySales.com for a directory of all the best sales in the UK. Any income gained via affiliate links keeps MedWorm running.




Chemotherapy Pioneer James Holland, MD, Dies at 92 Chemotherapy Pioneer James Holland, MD, Dies at 92

Tue, 27 Mar 2018 15:09:45 +0100

Holland was known for his involvement in developing groundbreaking cooperative clinical trial protocols for the treatment of leukemia and pioneering combination cancer chemotherapy.Medscape Medical News (Source: Medscape Medical News Headlines)



Phase III IMpower150 study showed Roche ’s TECENTRIQ (atezolizumab) and Avastin (bevacizumab) plus carboplatin and paclitaxel helped people with advanced lung cancer live longer compared to Avastin plus carboplatin and paclitaxel

Mon, 26 Mar 2018 05:00:00 +0100

Roche today announced that the Phase III IMpower150 study met its co-primary endpoint of overall survival (OS) at this interim analysis and showed that initial (first-line) treatment with the combination of TECENTRIQ ® (atezolizumab) and Avastin® (bevacizumab) plus carboplatin and paclitaxel (chemotherapy) helped people with advanced non-squamous non-small cell lung cancer (NSCLC) live significantly longer compared with Avastin plus carboplatin and paclitaxel. (Source: Roche Investor Update)



New family of promising, selective silver-based anti-cancer drugs discovered

Mon, 26 Mar 2018 04:00:00 +0100

(University of Johannesburg) A new family of potential silver-based anti-cancer drugs has been discovered by researchers in South Africa. The most promising complex among these has been successfully tested in rats and in several human cancer cell lines in laboratory studies. The complex is as effective against human esophageal cancer cells, as a widely-used chemotherapy drug, but at a ten times lower dose, and much lower toxicity against non-malignant cells. (Source: EurekAlert! - Medicine and Health)



Recurrent Endometrial Ca Responds to mTOR Drug

Sun, 25 Mar 2018 22:35:02 +0100

(MedPage Today) -- Responses in half of patients with no prior chemotherapy (Source: MedPage Today Hematology/Oncology)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.




Little known natural treatments for cancer blow away widely held myths

Sat, 24 Mar 2018 23:08:08 +0100

(Natural News) A cancer diagnosis is truly one of the most terrifying things a human can ever face. It is understandable that at such a time a person might be drawn to the apparent security of relying on the recommendations of the “qualified” doctor or oncologist who suggests a regimen of chemotherapy and/or radiation as... (Source: NaturalNews.com)



Biggest Change Since 2004 in NCCN Colon Cancer Chemo Guide Biggest Change Since 2004 in NCCN Colon Cancer Chemo Guide

Fri, 23 Mar 2018 14:07:42 +0100

For commonly occurring low-risk stage III colon cancers, the NCCN guidelines have been updated with findings from the IDEA trial supporting 3 months of chemotherapy instead of 6 months.Medscape Medical News (Source: Medscape Medical News Headlines)



New Targeted Therapy May Benefit Mesothelioma Patients

Fri, 23 Mar 2018 13:54:34 +0100

For newly diagnosed mesothelioma patients, standard treatment options include surgery, radiation therapy, chemotherapy and multimodal therapy, which combines these options in various ways. However, more physicians are adding precision medicine to the mix, including targeted therapies such as immunotherapy or drugs aimed at a specific genetic mutation in a tumor. Clinical trials have shown a new drug called AZD5363 attacks a gene that is mutated in some mesothelioma tumors. The drug was not designed for mesothelioma patients, but it may offer another mesothelioma treatment avenue in the future. Limited Options Inspire New Treatments Given how challenging it is to treat mesothelioma effectively, new therapies producing better results are needed. The experimental medication AZD5363 is one pot...



Breast Cancer Chemo Responders May Avoid Lymph Node Surgery Breast Cancer Chemo Responders May Avoid Lymph Node Surgery

Thu, 22 Mar 2018 18:21:50 +0100

Women with aggressive forms of breast cancer may be able to avoid lymph node surgery and its adverse effects if they respond well to chemotherapy, the results of two studies suggest.Medscape Medical News (Source: Medscape Medical News Headlines)



FDA Approval of Brentuximab Vedotin With Chemo Offers New Hope for Stage III/IV Hodgkin Lymphoma

Thu, 22 Mar 2018 17:45:00 +0100

Recent FDA approval of front-line brentuximab vedotin with chemotherapy in patients with stage III/IV Hodgkin lymphoma offers the first new treatment for this disease in over 40 years. (Source: CancerNetwork)

MedWorm Message: If you are looking to buy something in the January Sales please visit TheJanuarySales.com for a directory of all the best sales in the UK. Any income gained via affiliate links keeps MedWorm running.




Parasite Drug Shows Effectiveness Against Mesothelioma

Wed, 21 Mar 2018 14:40:14 +0100

Dr. Antonio Giordano believes his team has cleared the path to the next breakthrough in the treatment of malignant pleural mesothelioma. The advancement involves a new use for an old drug, pyrvinium pamoate, which doctors have successfully used for more than 50 years to treat infections of pinworm parasite. “This drug that no one expected to be involved with mesothelioma is potentially a new weapon against this aggressive type of tumor,” Giordano told Asbestos.com. “Our findings are exciting, very exciting. This one can move forward.” Giordano is the founder and director of the Sbarro Health Research Organization (SHRO) at Temple University in Philadelphia. He also is an internationally renowned professor of pathology and oncology at the University of Sienna in Italy. His expertise...



FDA Expands Approval of Adcetris (brentuximab vedotin) for First-Line Treatment of Stage III or IV Classical Hodgkin Lymphoma in Combination with Chemotherapy

Tue, 20 Mar 2018 22:03:58 +0100

March 20, 2018 -- The U.S. Food and Drug Administration today approved Adcetris (brentuximab vedotin) to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with... (Source: Drugs.com - New Drug Approvals)



FDA expands approval of Adcetris for first-line treatment of Stage III or IV classical Hodgkin lymphoma in combination with chemotherapy

Tue, 20 Mar 2018 18:31:00 +0100

FDA approves Adcetris (brentuximab vedotin) to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy (Source: Food and Drug Administration)



Seattle Genetics' Hodgkin's lymphoma drug wins U.S. approval

Tue, 20 Mar 2018 17:28:23 +0100

(Reuters) - U.S. regulators on Tuesday approved Seattle Genetics Inc's Adcetris as part of a chemotherapy cocktail to treat advanced Hodgkin's lymphoma in newly diagnosed patients, opening up a key market for the drugmaker. (Source: Reuters: Health)



Phase III IMpower131 study showed Roche ’s TECENTRIQ (atezolizumab) plus chemotherapy (carboplatin and Abraxane) reduced the risk of disease worsening or death in the initial treatment of people with a type of advanced squamous lung cancer

Tue, 20 Mar 2018 06:00:00 +0100

Roche today announced that the Phase III IMpower131 study met its co-primary endpoint of progression-free survival (PFS) and demonstrated that the combination of TECENTRIQ (atezolizumab) plus chemotherapy (carboplatin and Abraxane [albumin-bound paclitaxel; nab-paclitaxel]) reduced the risk of disease worsening or death (progression-free survival; PFS) compared with chemotherapy alone in the initial (first-line) treatment of people with advanced squamous non-small cell lung cancer (NSCLC). (Source: Roche Investor Update)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.